Cigna Group: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 5, 2020 and accepted by EDGAR at Nov 5, 2020, 12:22 ET.
Management's discussion and analysis
As filed, 90,717 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
| PAGE | |
|---|---|
| Executive Overview | 56 |
| Liquidity and Capital Resources | 66 |
| Critical Accounting Estimates | 70 |
| Segment Reporting | 70 |
| Evernorth | 71 |
| U.S. Medical | 73 |
| International Markets | 75 |
| Group Disability and Other | 77 |
| Corporate | 77 |
| Investment Assets | 78 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide information to assist you in better understanding and evaluating our financial condition as of September 30, 2020 compared with December 31, 2019 and our results of operations for the three and nine months ended September 30, 2020 compared with the same periods last year and intended to help you understand the ongoing trends in our business. We encourage you to read this MD&A in conjunction with our Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2019 (“2019 Form 10-K”), in particular the “Risk Factors” contained in Part I, Item 1A of that form as such Risk Factors are supplemented by the information contained in Part II, Item 1A of our Form 10-Q for the quarter ended March 31, 2020.
Unless otherwise indicated, financial information in the MD&A is presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). See Note 2 to the Consolidated Financial Statements in our 2019 Form 10-K for additional information regarding the Company’s significant accounting policies and Note 3 to the Consolidated Financial Statements in this Form 10-Q for updates to those accounting policies resulting from adopting new accounting guidance. The preparation of interim consolidated financial statements necessarily relies heavily on estimates. This and certain other factors call for caution in estimating full-year results based on interim results of operations. In some of our financial tables in this MD&A, we present either percentage changes or “N/M” when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points (“bps”).
In this MD&A, our consolidated measures “adjusted income from operations,” earnings per share on that same basis and “adjusted revenues” are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of “shareholders’ net income,” “earnings per share” and “total revenues.” We also use pre-tax adjusted income from operations and adjusted revenues to measure the results of our segments.
We use adjusted income from operations as our principal financial measure of operating performance because management believes it best reflects the underlying results of our business operations and permits analysis of trends in underlying revenue, expenses and profitability. We define adjusted income from operations as shareholders’ net income (or income before taxes for the segment metric) excluding realized investment gains and losses, amortization of acquired intangible assets, special items, and for periods prior to 2020, results of Anthem, Inc. and Coventry Health Care Inc. (“Coventry”) (collectively, the “transitioning clients”) (see the “Key Transactions and Business Developments” section of the MD&A for further discussion of transitioning clients). Cigna’s share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Income or expense amounts excluded from adjusted income from operations because they are not indicative of underlying performance or the responsibility of operating segment management include:
- Realized investment gains (losses) including changes in market values of certain financial instruments between balance sheet dates, as well as gains and losses associated with invested asset sales.
- Amortization of acquired intangible assets because these relate to costs incurred for acquisitions.
- Results of transitioning clients, for periods prior to 2020, because those results are not indicative of ongoing results.
- Special items, if any, that management believes are not representative of the underlying results of operations due to the nature or size of these matters.
The term "Adjusted revenues" is defined as total revenues excluding the following adjustments: revenue contribution from transitioning clients for periods prior to 2020, special items and Cigna’s share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to deliver affordable, personalized and innovative solutions for our customers and clients, in light of the challenges presented by the COVID-19 pandemic; future growth, business strategy, strategic or operational initiatives, including our organizational efficiency plan; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions, including the merger (“Merger”) with Express Scripts Holding Company and the sale of our U.S. Group Disability and Life business; our ongoing operational response to the COVID-19 pandemic; and other statements regarding Cigna’s future beliefs, expectations, plans, intentions, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical and pharmacy costs and price effectively; our ability to adapt to changes or trends in an evolving and rapidly changing industry; our ability to effectively differentiate our products and services from those of our competitors and maintain or increase market share; our ability to develop and maintain good relationships with physicians, hospitals, other health care providers, producers, consultants and pharmaceutical manufacturers; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing; the impact of modifications to our operations and processes; our ability to identify potential strategic transactions and realize the expected benefits (including anticipated synergies) of such transactions in full or within the anticipated time frame, including with respect to the Merger and the sale of our Group Disability and Life business, as well as our ability to integrate or separate operations, resources and systems; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions or guaranty fund assessments; uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems and those of our key suppliers or other third parties; the impact of our debt service obligations on the availability of funds for other business purposes; unfavorable industry, economic or political conditions, including foreign currency movements; acts of civil unrest, war, terrorism, natural disasters or pandemics; reinsurance credit risk, the scale and scope of the COVID-19 pandemic and its potential impact on our business, operating results, cash flows and financial condition, as well as on our employees, clients, customers, suppliers and partners and on the U.S. and global economies, as well as more specific risks and uncertainties discussed in Part I, Item 1A – Risk Factors of our 2019 Form 10-K, as such Risk Factors are supplemented by information contained in Part II, Item 1A of the Form 10-Q for the quarter ended March 31, 2020, Part II, Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of our 2019 Form 10-K and this MD&A and as described from time to time in our future reports filed with the Securities and Exchange Commission (the “SEC”).
You should not place undue reliance on forward-looking statements which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.
EXECUTIVE OVERVIEW
Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as “Cigna,” the “Company,” “we,” “our” or “us”) is a global health services organization with a mission of helping those we serve improve their health, well-being and peace of mind. We offer a differentiated set of pharmacy, medical, dental, disability, life and accident insurance and related products and services offered by our subsidiaries.
COVID-19 Update
The novel strain of coronavirus (“COVID-19”) was declared a pandemic by the World Health Organization in March 2020 because the virus had surfaced in nearly all regions around the world. From the onset of the COVID-19 pandemic, Cigna has focused on continuing to deliver peace of mind for the people and businesses we serve, and our employees and their families. We have taken actions to drive affordability, reduce uncertainty, and make health care easier. For customers, these actions include COVID-19 related cost share waivers, expanded access to virtual care, support for access to medication, and advocating for whole person health through various behavioral health initiatives. We have supported the medical community by simplifying processes and donating medications for a COVID-19 clinical trial. Cigna and the Cigna Foundation have assisted our communities through several initiatives including the launch of the Brave of Heart Fund that provides financial assistance to survivors of front-line U.S. healthcare workers who gave their lives in the fight against COVID-19. Cigna also provides emotional support services to their families.
We have continued to support our workforce by enabling remote work where appropriate, implementing enhanced safety protocols and programs that support the health and mental well-being of our employees. We have continued to execute our business continuity plans over our operations such as leveraging purchasing volume across the pharmaceutical supply chain in order to mitigate risk associated with prescription drug supply. We did not incur significant disruptions to our operations during the three and nine months ended September 30, 2020 from COVID-19.
We will continue to work with our clients, customers, providers and employees to provide support during the pandemic.
The COVID-19 pandemic has pervasively impacted the economy, financial markets and the global health care delivery systems. The effects of the COVID-19 pandemic on the Company began to emerge in the U.S. at the end of the first quarter and were not material to the Company's results of operations or financial condition for that period. Beginning in April, we experienced a significant deferral of care by our customers. The deferral of care moderated over the course of the second quarter with utilization levels eventually returning to nearly normal levels by the end of June. As expected, in the third quarter we experienced medical utilization at more typical levels as we observed a reduction to the level of deferred care and our customers sought care for COVID-19 testing and treatment. These impacts were most prevalent in the U.S. Medical segment where quarterly earnings reflect the impacts of COVID-19 including the return of medical utilization to more typical levels, costs of COVID-19 care as well as the costs of actions we have taken to support customers and providers, decreased contributions from our specialty products, and lower net investment income. Higher year to date U.S. Medical results reflect deferral of care by our customers in April and May that exceeded the cost of COVID-19 testing and treatment, the cost of COVID-19 related actions including premium relief programs for employer clients as well as cost share waivers for customers, and lower net investment income. Our Group Disability and Other results reflect significantly elevated life insurance claims related to the COVID-19 pandemic and its effects in the third quarter. Quarterly and year to date earnings in our Evernorth segment also reflected effects of the pandemic, specifically, a favorable mix of claims as a result of both the type of drugs dispensed as well as the distribution method used for dispensing and fulfilling, partially offset by lower non-specialty, 30-day retail script volume. Segment results are discussed further in the Segment Reporting section of this MD&A and discussion of the impact of COVID-19 on our investment portfolio and related considerations regarding our investment outlook can be found in Note 11 to the Consolidated Financial Statements and in the "Investment Assets" discussion of this MD&A, respectively.
While it is difficult to quantify the impact of the COVID-19 pandemic on our results for the remainder of 2020 and beyond, we believe that such results may be impacted by, among other things, lower customer volumes due to rising unemployment levels, higher medical costs to treat those affected by the virus or those who defer care, the return of costs related to previously deferred care, the potential for continued deferral of care, higher life insurance claims, lower investment returns, or lower future risk adjustment revenue due to disrupted care impeding appropriate documentation of customer risk profiles.
The Company has taken actions to enhance our liquidity that, combined with our other sources of liquidity described in the "Liquidity and Capital Resources Outlook" below, and our current projections for operating cash flows, we believe are sufficient to support our operations and meet our obligations.
The situation surrounding COVID-19 remains fluid, and we are actively managing our response and assessing impacts to our financial position and operating results, as well as adverse developments in our business.
For further information regarding the potential impact of COVID-19 on the Company, please see “Risk Factors” contained in Part I, Item 1A of the 2019 Form 10-K as such Risk Factors are supplemented in Part II, Item 1A of the Form 10-Q for the quarter ended March 31, 2020.
See Note 1 to the Consolidated Financial Statements for a description of our segments. Unless otherwise specified, the commentary provided below describes our results for the three and nine months ended September 30, 2020 compared with the same periods in 2019.
Summarized below are certain key measures of our performance by segment for the three and nine months ended September 30, 2020 and 2019:
Financial highlights by segment
(Dollars in millions, except per share amounts)
| Revenues Adjusted revenues by segment | Three Months Ended September 30, 2020 | 2019 | % Change | Nine Months Ended September 30, 2020 | 2019 | % Change |
|---|---|---|---|---|---|---|
| Evernorth | $29,827 | $24,880 | 20% | $85,597 | $70,877 | 21% |
| U.S. Medical | 9,629 | 9,148 | 5 | 28,726 | 27,311 | 5 |
| International Markets | 1,440 | 1,402 | 3 | 4,342 | 4,185 | 4 |
| Group Disability and Other | 1,314 | 1,284 | 2 | 3,981 | 3,889 | 2 |
| Corporate, net of eliminations | (1,409) | (881) | (60) | (4,248) | (2,625) | (62) |
| Adjusted revenues | 40,801 | 35,833 | 14 | 118,398 | 103,637 | 14 |
| Revenue contribution from transitioning clients | — | 2,718 | N/M | — | 11,657 | N/M |
| Net realized investment results from certain equity method investments | 37 | 5 | N/M | 87 | 27 | 222 |
| Special items | 117 | — | N/M | 204 | — | N/M |
| Total revenues | $40,955 | $38,556 | 6% | $118,689 | $115,321 | 3% |
| Shareholders’ net income | $1,388 | $1,351 | 3% | $4,323 | $4,127 | 5% |
| Adjusted income from operations | $1,618 | $1,718 | (6)% | $5,528 | $4,856 | 14% |
| Earnings per share (diluted) | ||||||
| Shareholders’ net income | $3.78 | $3.57 | 6% | $11.66 | $10.83 | 8% |
| Adjusted income from operations | $4.41 | $4.54 | (3)% | $14.91 | $12.74 | 17% |
| Pre-tax adjusted income from operations by segment | ||||||
| Evernorth | $1,443 | $1,399 | 3% | $3,774 | $3,555 | 6% |
| U.S. Medical | 757 | 953 | (21) | 3,479 | 3,113 | 12 |
| International Markets | 208 | 194 | 7 | 809 | 607 | 33 |
| Group Disability and Other | 70 | 143 | (51) | 279 | 376 | (26) |
| Corporate, net of eliminations | (366) | (442) | 17 | (1,171) | (1,385) | 15 |
| Consolidated pre-tax adjusted income from operations | 2,112 | 2,247 | (6) | 7,170 | 6,266 | 14 |
| Adjustment for transitioning clients | — | 274 | N/M | — | 1,589 | N/M |
| Income attributable to noncontrolling interests | 10 | 4 | 150 | 27 | 13 | 108 |
| Net realized investment gains (losses) | 69 | 56 | 23 | 69 | 111 | (38) |
| Amortization of acquired intangible assets | (493) | (734) | 33 | (1,487) | (2,214) | 33 |
| Special items | 106 | (84) | N/M | (289) | (456) | 37 |
| Income before income taxes | $1,804 | $1,763 | 2% | $5,490 | $5,309 | 3% |
For further analysis and explanation of each segment’s results, see the “Segment Reporting” section of this MD&A.
(Dollars in millions)
| Consolidated Results of Operations (GAAP basis) | Three Months Ended September 30, 2020 | 2019 | % Change | Nine Months Ended September 30, 2020 | 2019 | % Change |
|---|---|---|---|---|---|---|
| Pharmacy revenues | $27,802 | $25,987 | 7% | $79,464 | $77,454 | 3% |
| Premiums | 10,682 | 9,935 | 8 | 31,928 | 29,709 | 7 |
| Fees and other revenues | 2,174 | 2,285 | (5) | 6,424 | 7,123 | (10) |
| Net investment income | 297 | 349 | (15) | 873 | 1,035 | (16) |
| Total revenues | 40,955 | 38,556 | 6 | 118,689 | 115,321 | 3 |
| Pharmacy and other service costs | 26,624 | 24,552 | 8 | 76,425 | 73,565 | 4 |
| Medical costs and other benefit expenses | 8,429 | 7,734 | 9 | 23,863 | 22,930 | 4 |
| Selling, general and administrative expenses | 3,301 | 3,413 | (3) | 10,106 | 10,096 | — |
| Amortization of acquired intangible assets | 493 | 734 | (33) | 1,487 | 2,214 | (33) |
| Total benefits and expenses | 38,847 | 36,433 | 7 | 111,881 | 108,805 | 3 |
| Income from operations | 2,108 | 2,123 | (1) | 6,808 | 6,516 | 4 |
| Interest expense and other | (336) | (411) | 18 | (1,101) | (1,291) | 15 |
| Debt extinguishment costs | — | — | N/M | (199) | — | N/M |
| Net realized investment gains (losses) | 32 | 51 | (37) | (18) | 84 | N/M |
| Income before income taxes | 1,804 | 1,763 | 2 | 5,490 | 5,309 | 3 |
| Total income taxes | 406 | 409 | (1) | 1,143 | 1,173 | (3) |
| Net income | 1,398 | 1,354 | 3 | 4,347 | 4,136 | 5 |
| Less: Net income attributable to noncontrolling interests | 10 | 3 | 233 | 24 | 9 | 167 |
| Shareholders’ net income | $1,388 | $1,351 | 3% | $4,323 | $4,127 | 5% |
| Consolidated effective tax rate | 22.5% | 23.2% | (70) bps | 20.8% | 22.1% | (130) bps |
| Medical customers (in thousands) | ||||||
| U.S. Medical | 15,314 | 15,495 | (1)% | |||
| International Markets | 1,668 | 1,576 | 6 | |||
| Total | 16,982 | 17,071 | (1)% |
59
Reconciliation of Shareholders’ Net Income (GAAP) to Adjusted Income from Operations
$ in millions
| Three Months Ended September 30, 2020 | 2019 | Nine Months Ended September 30, 2020 | 2019 | Diluted Earnings Per Share Three Months Ended September 30, 2020 | 2019 | Nine Months Ended September 30, 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Shareholders’ net income | $1,388 | $1,351 | $4,323 | $4,127 | $3.78 | $3.57 | $11.66 | $10.83 |
| After-tax adjustments required to reconcile to adjusted income from operations | ||||||||
| Net realized investment (gains) losses | (64) | (49) | (75) | (100) | (0.17) | (0.13) | (0.20) | (0.26) |
| Amortization of acquired intangible assets | 376 | 558 | 1,061 | 1,694 | 1.02 | 1.47 | 2.86 | 4.43 |
| Adjustment for transitioning clients | — | (207) | — | (1,217) | — | (0.55) | — | (3.19) |
| Special items | ||||||||
| Integration and transaction-related costs | 83 | 88 | 256 | 311 | 0.23 | 0.24 | 0.69 | 0.82 |
| Debt extinguishment costs | — | — | 151 | — | — | — | 0.41 | — |
| Charge for organizational efficiency plan | — | — | 24 | — | — | — | 0.06 | — |
| (Benefits) charges associated with litigation matters | — | (23) | 19 | 41 | — | (0.06) | 0.05 | 0.11 |
| Risk corridors recovery | (76) | — | (76) | — | (0.21) | — | (0.20) | — |
| Contractual adjustment for a former client | (89) | — | (155) | — | (0.24) | — | (0.42) | — |
| Total special items | (82) | 65 | 219 | 352 | (0.22) | 0.18 | 0.59 | 0.93 |
| Adjusted income from operations | $1,618 | $1,718 | $5,528 | $4,856 | $4.41 | $4.54 | $14.91 | $12.74 |
Commentary: Three and Nine Months Ended September 30, 2020 versus the same periods in 2019
Unless indicated otherwise, the commentary presented below, and in the segment discussions that follow, compare results for the three and nine months ended September 30, 2020 with results for the three and nine months ended September 30, 2019.
Earnings and Revenue
Shareholders’ net income. The increase for the three months ended September 30, 2020 compared with the same period in 2019 was driven by lower amortization for customer-related intangibles associated with transitioning clients and the risk corridors claim recovery (see Risk Mitigation Programs - Individual ACA Business section of this MD&A and Note 18 to the Consolidated Financial Statements for further discussion), partially offset by the absence of earnings from transitioning clients and lower adjusted income from operations. For the nine months ended September 30, 2020, shareholders' net income increased compared with the same period in 2019, primarily due to higher adjusted income from operations and lower amortization, partially offset by the absence of earnings from transitioning clients.
Adjusted income from operations. The decrease for the three months ended September 30, 2020 compared with the same period in 2019 reflects impacts of COVID-19 in the U.S. Medical segment and unfavorable life claims experience in Group Disability and Other segment. Adjusted income from operations increased for the nine months ended September 30, 2020 compared with the same period in 2019, driven in part by higher earnings in the U.S. Medical and International segments resulting from the deferral of care in April and May due to the COVID-19 pandemic. Also contributing to the increase were higher Evernorth segment earnings reflecting customer growth and increased script volumes, and lower interest costs in Corporate driven by debt repayments.
Medical customers decreased slightly as of September 30, 2020 compared with the same period last year primarily as a result of declines in the National Accounts market segment and increased disenrollment driven by the impacts of COVID-19. Those decreases were partially offset by growth in the Select, International and Medicare Advantage market segments.
Pharmacy revenues increased, primarily reflecting the transition of U.S. Medical's customers to Evernorth, higher claims volumes, primarily driven by the Evernorth collaboration with Prime Therapeutics, and an increase in pricing, primarily due to inflation on branded drugs. These factors were substantially offset by the absence of revenues from the transitioning clients and, to a lesser extent, an increase in generic fill rate. See the Evernorth segment section of this MD&A for further discussion of pharmacy revenues.
Premiums increased, primarily resulting from customer growth in insured products and rate increases reflecting expected medical cost inflation and the return of the health insurance industry tax. These factors were partially offset by the impact of premium relief programs implemented in response to significantly lower than historical utilization as individuals deferred care in April and May due to the COVID-19 pandemic.
Fees and other revenues decreased, primarily reflecting the transition of U.S. Medical's commercial customers to Evernorth's retail pharmacy network beginning in the third quarter of 2019 (see Note 2(K) to the Consolidated Financial Statements included in our 2019 Form 10-K for further information).
Net investment income decreased, primarily driven by lower yields, including lower income from partnership investments due to current economic conditions. These effects were partially offset by higher average assets. See the Investment Asset section of this MD&A for further discussion.
Other Components of Consolidated Results of Operations
- Pharmacy and other service costs increased, primarily reflecting the transition of U.S. Medical's customers to Evernorth, higher claims volumes, primarily driven by the Evernorth collaboration with Prime Therapeutics, and an increase in pricing, primarily due to inflation on branded drugs. These factors were substantially offset by the impact of the absence of the transitioning clients and, to a lesser extent, effective management of supply chain and the favorable impact of the mix of claims.
- Medical costs and other benefit expenses increased, reflecting both medical cost trend and customer growth in insured products in U.S. Medical and higher life claims in Group Disability and Other due to the effects of the COVID-19 pandemic.
- Selling, general and administrative expenses decreased slightly for the three months and were essentially flat for the nine months ended September 30, 2020, compared with the same periods in 2019. These results primarily reflected the risk corridors claim recovery recognized in the third quarter of 2020 (see Risk Mitigation Programs - Individual ACA Business section of this MD&A and Note 18 to the Consolidated Financial Statements for further discussion) and lower costs associated with operations-related litigation and compliance costs (see the U.S. Medical section of this MD&A), offset by the return of the health insurance industry tax.
- Amortization of acquired intangible assets decreased, primarily reflecting lower amortization of customer-related intangibles associated with the transitioning clients.
- Consolidated effective tax rate decreased, driven by recognition of certain incremental federal and state tax benefits, partially offset by the return of the nondeductible health insurance industry tax.
Key Transactions and Business Developments
Merger with Express Scripts
As discussed in more detail in our 2019 Form 10-K, Cigna acquired Express Scripts on December 20, 2018 in a cash and stock transaction valued at $52.8 billion. Costs related to this transaction are reported in “integration and transaction-related costs” as a special item and excluded from adjusted income from operations because they are not indicative of future underlying performance of the business.
On January 30, 2019, Anthem exercised its early termination right and terminated its pharmacy benefit management services agreement with us, effective March 1, 2019. There was a twelve-month transition period that ended March 1, 2020. We excluded the results of Express Scripts’ contract with Anthem (and also Coventry) from our non-GAAP reporting metrics “adjusted revenues” and “adjusted income from operations” for 2019 and refer to these clients as “transitioning clients.” As of December 31, 2019, the transition was substantially complete; therefore, beginning in 2020, we no longer exclude results of transitioning clients from our reported adjusted revenues and adjusted income from operations.
Agreement to sell Group Disability and Life business
As discussed in Note 6 to the Consolidated Financial Statements, Cigna entered into a definitive agreement in December 2019 to sell the U.S. Group Disability and Life business to New York Life Insurance Company for $6.3 billion. The “Liquidity” section of this MD&A provides further discussion of the impact of this pending divestiture on our liquidity and capital resources.
Organizational Efficiency Plan
Consistent with our commitment to affordability for our customers and clients, during the fourth quarter of 2019 the Company committed to a plan to increase our organizational alignment and operational efficiency and reduce costs. As a result, we recognized a charge in Selling, general and administrative expenses of $207 million, pre-tax ($162 million, after-tax) in the fourth quarter of 2019 and an additional charge of $31 million pre-tax ($24 million, after-tax) in the first quarter of 2020. We expect to realize annualized after-tax savings of approximately $200 million. A substantial portion of the savings will be realized in 2020. See Note 15 to the Consolidated Financial Statements for discussion.
Industry Developments and Other Matters
Our 2019 Form 10-K provides a detailed description of The Patient Protection and Affordable Care Act (“ACA”) provisions and other legislative initiatives that impact our health care and pharmacy services businesses, including regulations issued by the Centers for Medicare & Medicaid Services (“CMS”) and the Departments of the Treasury and Health and Human Services. The health care and pharmacy services businesses continue to operate in a dynamic environment, and the laws and regulations applicable to these businesses, including the ACA, continue to be subject to legislative, regulatory and judicial challenges. The following table provides an update on the expected impact of these items and other matters:
| Item | Description |
|---|---|
| Executive Orders Regarding Drug Pricing | On July 24, 2020, President Trump signed four Executive Orders addressing prescription drug importation; affordability of insulin and epinephrine purchased at federally qualified health centers through the Public Health Service Act Section 340B drug pricing program; drug rebates and most favored-nation international pricing. The release of the most favored-nation international pricing order, an approach to international reference pricing, was delayed and a revised order was issued on September 13, 2020. All four orders call for subsequent policy action by the Department of Health and Human Services (HHS). They do not contain any policy changes that take effect immediately. The order covering rebate policy directs HHS to complete prior rulemaking which proposed changes to the federal anti-kickback safe harbor to exclude regulatory protection for rebates between drug manufacturers and Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers. This order also requires that prior to taking such action, the Secretary of HHS confirm that the action is not projected to increase federal spending, Medicare beneficiary premiums or customers’ total out-of-pocket costs. In late September 2020, HHS released a rule intended to allow importation of certain prescription drugs from Canada under the Federal Food, Drug and Cosmetic Act, effective November 30, 2020, as well as guidance to pharmaceutical manufacturers related to importation or reimportation of certain products. Also in late September, HHS released a proposed rule that would implement the program to make insulin and epinephrine available at Section 340B pricing at participating federally qualified health centers. Comments on the proposed rule were due in late October. President Trump signed an additional Executive Order on September 24, 2020 directing HHS to take various actions to expand upon existing actions to provide Americans more choice, lower costs, and better healthcare. The September 24 Order specifically calls on HHS, in coordination with the Commissioner of Food and Drugs, to continue to expand access to affordable medications, including accelerating approvals of new generic and biosimilar drugs and facilitating safe importation of prescription drugs. The Company is continuing to monitor actions related to the Executive Orders and expects any final regulations, in the aggregate, will not have a material impact on our business. |
| Transparency in Coverage | On October 29, 2020, the HHS, the Department of Labor and the Department of the Treasury issued a final rule which requires most group health plans and health insurance issuers in the individual and group markets to disclose price and cost-sharing information for all items and services to participants and enrollees. The cost-sharing information requirements under the rule take effect in a phased approach beginning January 1, 2023. In addition to providing personalized cost-sharing information, health plans and health insurers must also publicly disclose in-network provider negotiated rates and historical out-of-network allowed amounts beginning January 1, 2022. Beginning in 2021, insurers will be able to receive credit in their medical loss ratio calculations for certain savings they share with enrollees. We will continue to work with policymakers and our clients and customers on the implications of the rule. |
| COVID-19-related Regulatory Actions | In response to the COVID-19 public health emergency, U.S. federal and state governments have increasingly enacted new regulatory requirements, as well as provided additional flexibility to industry participants. These regulatory actions primarily provide for: •client and customer premium relief to avoid the cancellation or non-renewal of policies; •mandating or requesting waiver of customer cost-sharing and other associated costs related to COVID-19 testing or treatment, as well as establishing provider reimbursement and future vaccine immunizations coverage requirements; •extending claims filing deadlines for providers, customers and facilities; •mandating or encouraging waiver of customer cost-share related to telemedicine services, as well as requiring certain reimbursement levels for telemedicine providers to encourage its utilization; •enacting coverage and reimbursement requirements at in-network levels for certain services received from out-of-network providers; •revising or suspending the use of certain medical management procedures; and •mandating prescription drug benefit administration requirements primarily related to formulary exceptions and restrictions, and prior authorization and prescription drug refill limits. We are diligently working with federal, state and local governments to deliver access to simple, affordable and predictable health care and continue to monitor developments. |
63
| Medicare Advantage ("MA") | Medicare Star Quality Ratings ("Star Ratings"): CMS uses a Star Rating system to measure how well MA plans perform and scores performance in several categories, including quality of care and customer service. Star Ratings range from one to five stars. CMS recognizes plans with Star Ratings of four stars or greater with quality bonus payments and the ability to offer enhanced benefits. Approximately 77% of our MA customers were in four star or greater plans for bonus payments received in 2020 and 87% for bonus payments to be received in 2021. In October 2020, CMS announced the Star Ratings for bonus payments to be received in 2022. We expect the percentage of our MA customers in four star or greater plans will increase to 88% for bonus payments to be received in 2022. |
| MA Rates: Final MA reimbursement rates for 2021 were published by CMS in April 2020. We do not expect the new rates to have a material impact on our consolidated results of operations in 2021. | |
| Risk Adjustment: As discussed in the “Regulation” and “Risk Factors” sections of our 2019 Form 10-K, our MA business is subject to reviews, including risk adjustment data validation (“RADV”) audits by CMS and the Office of the Inspector General (“OIG”). We expect that CMS, OIG and other federal agencies will continue to closely scrutinize components of the Medicare program. | |
| The “Regulation” section of the 2019 Form 10-K also discusses a proposed rule issued by CMS in 2018 for RADV audits of contract year 2011 and all subsequent years that included, among other things, extrapolation of the error rate related to RADV audit findings without applying the adjustment for underlying fee-for-service data errors as currently contemplated by CMS’ RADV audit methodology. RADV audits for our contract years 2011 through 2015 are currently in process. CMS has announced its intent to use third-party auditors to audit all Medicare Advantage contracts by either a comprehensive or a targeted RADV review for each contract year. If the proposed rule is adopted in its current form, it could result in some combination of degraded plan benefits, higher monthly premiums and reduced choice for the population served by all MA insurers. The Company, along with other MA organizations and additional interested parties, submitted comments to CMS on the proposed rule as part of the notice-and-comment rulemaking process. The comment period concluded on August 28, 2019. If CMS adopts the rule as proposed, there could be a material impact on the Company’s future results of operations, though we expect the rule would be subject to legal challenges. In addition, the Company is subject to OIG RADV audits that are in process. Previously suspended CMS and OIG audit activities have resumed. | |
| Also, as described in Note 18 to the Consolidated Financial Statements, the U.S. Department of Justice is currently conducting an industry-wide investigation of risk adjustment data submission practices and business processes, which in the case of certain other MA organizations has resulted in litigation. |
64
| Item | Description |
|---|---|
| Affordable Care Act | Cost-Sharing Reduction Subsidies: The ACA provides for cost-sharing reductions that offset the amount that qualifying customers pay for deductibles, copays and coinsurance. The federal government stopped funding insurers for the cost-sharing reduction subsidies in 2017. Certain insurers have sued the federal government for failure to pay cost-sharing reduction subsidies and the matter remains unresolved. In the first set of consolidated appeals, the Court of Appeals for the Federal Circuit issued a decision on August 14, 2020, finding that (i) the CSR reimbursement provision of the ACA imposes an obligation on the government to pay, and (ii) the government’s payments must be reduced by the amount of additional premium tax credit payments that each insurer received as a result of the government’s termination of CSR payments. On September 28, 2020, the insurers filed a petition for rehearing en banc in the Federal Circuit and that petition remains pending before the court. As described in Note 18 to the Consolidated Financial Statements, we filed a lawsuit in May 2020 against the federal government seeking payment of these subsidies and our case is stayed pending the outcome of the consolidated appeals currently pending in the Federal Circuit. Our premium rates for the 2018, 2019 and 2020 plan years reflected a lack of government funding for cost-sharing reduction subsidies. |
| ACA Litigation: As described in the “Business - Regulation” section of our 2019 Form 10-K, a federal district court ruled that the “individual mandate” in the ACA is unconstitutional. On appeal, the Court of Appeals for the Fifth Circuit agreed that the “individual mandate” is unconstitutional but ordered the district court to reexamine whether the other provisions of the ACA can remain in effect, thereby leaving in doubt whether the entire ACA is unconstitutional until there is a final judicial determination on appeal. The California-led states and the U.S. House of Representatives filed petitions seeking to appeal the Fifth Circuit's ruling to the U.S. Supreme Court. On March 2, 2020, the Supreme Court agreed to hear the appeals and the case is scheduled to be argued before the Supreme Court on November 10, 2020. |
Risk Mitigation Programs – Individual ACA Business
Risk Corridors. In 2016, we recorded an allowance for the balance of our ACA risk corridors receivable based on court decisions and the large program deficit. On April 27, 2020, the U.S. Supreme Court ruled that insurers are entitled to the full amount due under the risk corridors program. The Supreme Court remanded the cases before it to the lower courts for further proceedings consistent with its opinion. We filed a lawsuit in May 2020 seeking payment of these funds. We received $120 million in payments in September 2020, which resolved our risk corridors claim. See Note 18 to the Consolidated Financial Statements for further information.
Risk Adjustment. Following each program year, risk adjustment balances are subject to audit adjustment by CMS through the RADV program. RADV audits commenced with the 2017 benefit year. CMS published the final RADV transfers for the 2017 benefit year in 2019 along with guidance that the settlement will not take place until 2021. The 2018 benefit year data validation error rates were released by CMS in June 2020 and the RADV transfers were published by CMS in August 2020, subject to an appeals period with final settlement expected in 2022. Based on the information currently available, we adjusted our risk adjustment balance to reflect the expected outcome of the RADV program.
The following table presents our balances associated with the risk adjustment program and RADV audit adjustments as of September 30, 2020 and December 31, 2019.
(In millions)
| Risk Adjustment | Receivable (Payable) Balances September 30, 2020 | December 31, 2019 |
|---|---|---|
| Receivables (1) | $110 | $47 |
| Payables (2) | $(121) | $(213) |
(1) Receivables, net of allowances, are reported in Accounts receivable, net in the Consolidated Balance Sheets.
(2) Payables are reported in Accrued expenses and other liabilities (current) in the Consolidated Balance Sheets.
Risk adjustment program activity, including any RADV adjustments, was favorable by $7 million pre-tax ($5 million after tax) for the three months and $21 million pre-tax ($17 million after tax) for the nine months ended September 30, 2020 compared with charges of $18 million pre-tax ($14 million after-tax) and $134 million pre-tax ($103 million after-tax) for the same periods in 2019.
LIQUIDITY AND CAPITAL RESOURCES
Liquidity
We maintain liquidity at two levels: the subsidiary level and the parent company level.
Liquidity requirements at the subsidiary level generally consist of:
- pharmacy, medical costs and other benefit payments;
- expense requirements, primarily for employee compensation and benefits, information technology and facilities costs;
- income taxes; and
- debt service.
Our subsidiaries normally meet their liquidity requirements by:
- maintaining appropriate levels of cash, cash equivalents and short-term investments;
- using cash flows from operating activities;
- matching investment durations to those estimated for the related insurance and contractholder liabilities;
- selling investments; and
- borrowing from affiliates, subject to applicable regulatory limits.
Liquidity requirements at the parent company level generally consist of:
- debt service and dividend payments to shareholders;
- lending to subsidiaries as needed; and
- pension plan funding.
The parent company normally meets its liquidity requirements by:
- maintaining appropriate levels of cash and various types of marketable investments;
- collecting dividends from its subsidiaries;
- using proceeds from issuing debt and common stock; and
- borrowing from its subsidiaries, subject to applicable regulatory limits.
Dividends from our insurance, Health Maintenance Organization (“HMO”) and foreign subsidiaries are subject to regulatory restrictions. See Note 20 to the Consolidated Financial Statements in our 2019 Form 10-K for additional information regarding these restrictions. Most of Express Scripts' subsidiaries are not subject to regulatory restrictions regarding dividends and therefore provide significant financial flexibility to Cigna.
Cash flows for the nine months ended September 30 were as follows:
(In millions)
| Nine Months Ended September 30, 2020 | 2019 | |
|---|---|---|
| Operating activities | $6,056 | $6,692 |
| Investing activities | $(1,444) | $(463) |
| Financing activities | $(3,812) | $(5,480) |
The following discussion explains variances in the various categories of cash flows for the nine months ended September 30, 2020 compared with the same period in 2019.
Operating activities
Cash flows from operating activities consist principally of cash receipts and disbursements for pharmacy revenues and costs, premiums, fees, investment income, taxes, benefit costs and other expenses.
Cash flows from operating activities decreased, primarily driven by an increase in accounts receivable due to business growth, higher inventory purchases and resumption of the health insurance industry tax payment, offset by higher pharmacy and services costs payable due to business growth.
Investing and Financing activities
Cash used in investing activities increased, primarily due to higher net investment purchases.
Cash used in finance activities decreased, primarily due to higher proceeds from issuance of debt, partially offset by higher debt repayments and stock repurchases.
We maintain a share repurchase program authorized by our Board of Directors. Under this program, we may repurchase shares from time to time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors including price, general business and market conditions and alternate uses of capital. The share repurchase program may be effected through open market purchases or privately negotiated transactions in compliance with Rule 10b-18 under the Securities Exchange Act of
1934, as amended, including through Rule 10b5-1 trading plans. The program may be suspended or discontinued at any time.
For the nine months ended September 30, 2020, we repurchased 13.2 million shares for approximately $2.4 billion. From October 1, 2020 through November 4, 2020 we repurchased 2.8 million shares for approximately $500 million. Share repurchase authority was $3.1 billion as of November 4, 2020.
Capital Resources
Our capital resources (primarily cash flows from operating activities and proceeds from the issuance of debt and equity securities) provide protection for policyholders, furnish the financial strength to underwrite insurance risks and facilitate continued business growth.
In December 2019, Cigna entered into a definitive agreement to sell the U.S. Group Disability and Life business to New York Life Insurance Company for $6.3 billion. The sale is expected to close in the fourth quarter of 2020 subject to applicable regulatory approvals and other customary closing conditions. Cigna estimates approximately $5.3 billion of net after-tax proceeds from this transaction and expects to use these proceeds primarily for share repurchase and repayment of debt.
In 2018, Cigna entered into a $3.25 billion five-year revolving credit agreement and a $3.0 billion term loan credit agreement in financing the Express Scripts acquisition. The term loan was repaid in full and the term loan credit agreement was terminated in the fourth quarter of 2019.
In 2019, Cigna entered into an additional $1 billion 364-day revolving credit agreement that expired in October 2020. In October 2020, Cigna replaced the revolving credit agreement with a new $1.0 billion 364-day revolving credit agreement which will expire in October 2021.
As of September 30, 2020, there were no outstanding balances under either of the revolving credit agreements.
On April 1, 2020, the Company borrowed an aggregate principal amount of $1.4 billion under a new 364-day term loan credit agreement. The Company entered into this agreement to further enhance its liquidity position in light of disruption in the commercial paper market and used a portion of the proceeds to pay down amounts outstanding under its commercial paper facility. See Note 8 to the Consolidated Financial Statements for further information on our credit agreements.
At September 30, 2020, our debt-to-capitalization ratio was 42.8%, a decline from 45.2% at December 31, 2019. We have a near-term focus on accelerated debt repayment and expect to continue to deleverage to below 40% using cash flows from operating activities and a portion of the proceeds from the sale of the Group Disability and Life business.
Management, guided by regulatory requirements and rating agency capital guidelines, determines the amount of capital resources that we maintain. Management allocates resources to new long-term business commitments when returns, considering the risks, look promising and when the resources available to support existing business are adequate.
We prioritize our use of capital resources to:
- provide the capital necessary to support growth and maintain or improve the financial strength ratings of subsidiaries and to fund pension obligations;
- consider acquisitions that are strategically and economically advantageous; and
- return capital to investors primarily through share repurchases.
Our capital management strategy to support the liquidity and regulatory capital requirements of our foreign operations and certain international growth initiatives is to retain overseas a significant portion of the earnings generated by our foreign operations. This strategy does not materially limit our ability to meet our liquidity and capital needs in the United States.
Liquidity and Capital Resources Outlook
We maintain sufficient liquidity to meet our cash needs through our cash and cash equivalents balances, cash flows from operations, commercial paper program, credit agreements, and the issuance of long-term debt. As of September 30, 2020, we had $4.25 billion of undrawn committed capacity under our revolving credit agreements, $1.7 billion of remaining capacity under our commercial paper program, and approximately $5.8 billion in cash and short-term investments, approximately $1.2 billion of which was held by the parent company or certain nonregulated subsidiaries. We actively monitor our debt obligations and engage in issuance or redemption activities as needed in accordance with our capital management strategy. A description of our outstanding debt can be found in Note 8 to the Consolidated Financial Statements.
During the nine months ended September 30, 2020, we made an immaterial pension contribution as required under the Pension Protection Act of 2006. We expect the required contributions for 2021 to be immaterial.
Our cash projections may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the Risk Factors section of our 2019 Form 10-K and Part II, Item 1A of the Form 10-Q for the quarter ended March 31, 2020. Though we believe we have adequate sources of liquidity, significant disruption or volatility in the capital and credit markets could affect our ability to access those markets for additional borrowings or increase costs. In addition to the sources of liquidity discussed above, the parent company can borrow an additional $0.9 billion from its subsidiaries without further approvals as of September 30, 2020.
Guarantees and Contractual Obligations
We are contingently liable for various contractual obligations entered into in the ordinary course of business. See Note 18 to the Consolidated Financial Statements for discussion of various guarantees.
We have updated long-term debt obligations as of September 30, 2020 previously provided in our 2019 Form 10-K. Investment commitments are described in Note 13 to the Consolidated Financial Statements. There have been no material changes to the other information presented in our table of guarantees and contractual obligations as set forth in our 2019 Form 10-K.
(In millions, on an undiscounted basis)
| On-Balance Sheet | Total | 2020 | 2021 to 2022 | 2023 to 2024 | Thereafter |
|---|---|---|---|---|---|
| Long-term debt(1) | 50,954 | 1,503 | 7,953 | 7,106 | 34,392 |
(1) Amounts include scheduled interest payments, current maturities of long-term debt and term loan borrowing. Finance leases are included in long-term debt and primarily represent obligations for information technology network storage, servers and equipment. See Note 16 to the Consolidated Financial Statements for information regarding finance leases. See Note 8 to the Consolidated Financial Statements for information regarding our long-term debt.
CRITICAL ACCOUNTING ESTIMATES
The preparation of Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures in the Consolidated Financial Statements. Management considers an accounting estimate to be critical if:
- it requires assumptions to be made that were uncertain at the time the estimate was made; and
- changes in the estimate or different estimates that could have been selected could have a material effect on our consolidated results of operations or financial condition.
Management has discussed how critical accounting estimates are developed and selected with the Audit Committee of our Board of Directors and the Audit Committee has reviewed the disclosures presented in our 2019 Form 10-K. We regularly evaluate items that may impact critical accounting estimates. Our most critical accounting estimates, as well as the effect of hypothetical changes in material assumptions used to develop each estimate, are described in the 2019 Form 10-K. As of September 30, 2020 there were no significant changes to the critical accounting estimates from what was reported in our 2019 Form 10-K.
Goodwill and Other Intangible Assets
Our annual evaluations of goodwill and other intangible assets for impairments were completed during the third quarter of 2020. These evaluations were performed at the reporting unit level, based on discounted cash flow analyses or market data. The estimated fair value of each of our reporting units exceeded their carrying values by significant margins.
Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate. However, if actual experience significantly differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the resulting changes could have a material adverse effect on our consolidated results of operations, and in certain situations, could have a material adverse effect on liquidity and our financial condition.
As discussed in the executive overview of this MD&A, the COVID-19 pandemic has pervasively impacted the economy, financial markets and the global health care delivery systems. If the impact of the COVID-19 pandemic over the remainder of 2020 and beyond is worse than management's current projections, these adverse effects to our business could impact the estimated fair value of our reporting units.
SEGMENT REPORTING
The following section of this MD&A discusses the results of each of our segments. See Note 1 to the Consolidated Financial Statements for a description of our segments.
In segment discussions, we present adjusted revenues and “pre-tax adjusted income from operations,” defined as income before taxes excluding realized investment gains (losses), amortization of acquired intangible assets, special items and, for periods prior to 2020, results of transitioning clients. Ratios presented in this segment discussion exclude the same items as pre-tax adjusted income from operations. See Note 19 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income before income taxes to pre-tax adjusted income from operations, as well as a reconciliation of total revenues to adjusted revenues. Note 19 to the
Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate.
In these segment discussions, we also present “pre-tax adjusted margin,” defined as pre-tax adjusted income from operations divided by adjusted revenues.
As of the third quarter 2020, the segment previously reported as Health Services is reported as Evernorth, and the segment previously reported as Integrated Medical is reported as U.S. Medical. There are no changes to the underlying business reported in either segment.
Evernorth Segment
Evernorth includes pharmacy services, benefits management, care solutions and data and analytics. As described in the introduction to Segment Reporting, Evernorth performance is measured using pre-tax adjusted income from operations.
The key factors that impact Evernorth revenues and costs of revenues are volume, mix of claims and price. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements included in our 2019 Form 10-K for additional information on revenue and cost recognition policies for this segment.
- As our clients’ claim volumes increase or decrease, our resulting revenues and cost of revenues correspondingly increase or decrease. Our gross profit could also increase or decrease as a result of changes in purchasing discounts.
- The mix of claims generally considers the type of drug and distribution method used for dispensing and fulfilling. Types of drugs can have an impact on our pharmacy revenues, pharmacy and other service costs and gross profit, including amounts payable under certain financial and performance guarantees with our clients. In addition to the types of drugs, the mix of generic claims (i.e., generic fill rate) also impacts our gross profit. Generally, higher generic fill rates reduce revenues, as generic drugs are typically priced lower than the branded drugs they replace. However, as ingredient cost paid to pharmacies on generic drugs is incrementally lower than the price charged to our clients, higher generic fill rates generally have a favorable impact on our gross profit. The home delivery generic fill rate is currently lower than the network generic fill rate as fewer generic substitutions are available among maintenance medications (such as therapies for chronic conditions) commonly dispensed from home delivery pharmacies as compared to acute medications that are primarily dispensed by pharmacies in our retail networks. Furthermore, our gross profit differs among network, home delivery and specialty distribution methods and can impact our profitability.
- Our client contract pricing is impacted by our ongoing ability to negotiate supply chain contracts for pharmacy network, pharmaceutical and wholesaler purchasing, and manufacturer rebates. As we seek to improve the effectiveness of our integrated solutions for the benefit of our clients, we are continuously innovating and optimizing the supply chain. Our gross profit could also increase or decrease as a result of supply chain initiatives implemented. Inflation also impacts our pricing because most of our contracts provide that we bill clients and pay pharmacies based on a generally recognized price index for pharmaceuticals. Therefore, the rate of inflation for prescription drugs and our efforts to manage this inflation for our clients can affect our revenues and cost of revenues.
In this MD&A, we present revenues and gross profit, as well as adjusted revenues and adjusted gross profit, consistent with our segment reporting metrics, which exclude special items and, for periods prior to 2020, contributions from transitioning clients. As of December 31, 2019, the transition of these clients was substantially complete; therefore, beginning in 2020, we no longer exclude results of transitioning clients from our adjusted metrics. See the “Key Transactions and Business Developments” section of our 2019 Form 10-K MD&A for further discussion of transitioning clients and why we present this information.
Results of Operations
(In millions)
| Financial Summary | Three Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) 2020 | Nine Months Ended September 30, 2019 | Change Favorable (Unfavorable) | |
|---|---|---|---|---|---|---|
| Total revenues | $29,944 | $27,598 | 9% | $85,801 | $82,534 | 4% |
| Less: Transitioning clients | — | (2,718) | N/M | — | (11,657) | N/M |
| Less: Contractual adjustment for a former client | (117) | — | N/M | (204) | — | N/M |
| Adjusted revenues(1) | $29,827 | $24,880 | 20% | $85,597 | $70,877 | 21% |
| Gross profit | $2,107 | $2,192 | (4)% | $5,589 | $6,631 | (16)% |
| Adjusted gross profit(1) | $1,990 | $1,880 | 6% | $5,385 | $4,887 | 10% |
| Pre-tax adjusted income from operations | $1,443 | $1,399 | 3% | $3,774 | $3,555 | 6% |
| Pre-tax adjusted margin | 4.8% | 5.6% | (80) bps | 4.4% | 5.0% | (60) bps |
(Dollars and adjusted scripts in millions)
| Selected Financial Information(1) Pharmacy revenue by distribution channel | Three Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) 2020 | Nine Months Ended September 30, 2019 | Change Favorable (Unfavorable) | |
|---|---|---|---|---|---|---|
| Adjusted network revenues | $14,522 | $10,911 | 33% | $41,179 | $29,937 | 38% |
| Adjusted home delivery and specialty revenues | 12,699 | 11,650 | 9% | 37,111 | 34,198 | 9% |
| Other revenues | 1,412 | 1,228 | 15% | 3,946 | 3,608 | 9% |
| Total adjusted pharmacy revenues | $28,633 | $23,789 | 20% | $82,236 | $67,743 | 21% |
| Pharmacy script volume | ||||||
| Adjusted network scripts(2) | 309 | 242 | 28% | 890 | 687 | 30% |
| Adjusted home delivery and specialty scripts(2) | 72 | 70 | 3% | 215 | 211 | 2% |
| Total adjusted scripts(2) | 381 | 312 | 22% | 1,105 | 898 | 23% |
| Generic fill rate | ||||||
| Network | 87.0% | 87.1% | (10) bps | 87.9% | 87.5% | 40 bps |
| Home delivery | 85.3% | 84.2% | 110 bps | 85.1% | 84.2% | 90 bps |
| Overall generic fill rate | 86.9% | 86.7% | 20 bps | 87.6% | 87.1% | 50 bps |
(1) Amounts exclude special items and, for periods prior to 2020, contributions from transitioning clients.
(2) Non-specialty network scripts filled through 90-day programs and home delivery scripts are multiplied by three. All other network and specialty scripts are counted as one script.
Three and Nine Months Ended September 30, 2020 versus Three and Nine Months Ended September 30, 2019
In the third quarter of 2019, U.S. Commercial operating segment customers transitioned to Express Scripts’ retail pharmacy network. In the first quarter of 2020, U.S. Government operating segment customers transitioned to Express Scripts’ retail pharmacy network.
Adjusted network revenues. The increase reflected the transition of U.S. Medical’s customers and higher claims volume, primarily due to our collaboration with Prime Therapeutics. For the nine months ended September 30, 2020, the increase was further driven by increased prices due to inflation on branded drugs, partially offset by claims mix due to the increase in the generic fill rate.
Adjusted home delivery and specialty revenues. The increase reflected higher prices, primarily due to inflation on branded drugs and higher home delivery and specialty claims volume. These increases were partially offset by claims mix due to an increase in the generic fill rate.
Adjusted gross profit. The increase reflected customer growth, higher adjusted pharmacy script volumes, benefits from the effective management of supply chain, and the favorable impact of claims mix as a result of the types of drugs dispensed, the distribution method used for dispensing and fulfilling, and an increase in the generic fill rate.
Pre-tax adjusted income from operations. The increase reflected customer growth, higher adjusted pharmacy scripts volumes, benefits from the effective management of supply chain, and the favorable impact of claims mix as a result of the types of drugs dispensed, the distribution method used for dispensing and fulfilling, and an increase in the generic fill rate, partially offset by an increase in operating expenses due to client transitions.
U.S. Medical Segment
U.S. Medical consists of a U.S. Commercial operating segment that includes our employer-sponsored medical coverage and a U.S. Government operating segment that includes Medicare offerings for seniors and individual insurance offerings both on and off the public health insurance exchanges. As described in the introduction to Segment Reporting, performance of the U.S. Medical segment is measured using pre-tax adjusted income from operations. Key factors affecting profitability for this segment include:
- customer growth;
- revenues from integrated specialty products, including pharmacy services sold to clients and customers across all funding solutions;
- percentage of Medicare Advantage customers in plans eligible for quality bonus payments;
- benefit expenses as a percentage of premiums (medical care ratio or “MCR”) for our insured commercial and government businesses; and
- selling, general and administrative expense as a percentage of adjusted revenues (expense ratio).
Results of Operations
(In millions)
| Financial Summary | Three Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) 2020 | Nine Months Ended September 30, 2019 | Change Favorable (Unfavorable) | |
|---|---|---|---|---|---|---|
| Adjusted revenues | $9,629 | $9,148 | 5% | $28,726 | $27,311 | 5% |
| Pre-tax adjusted income from operations | $757 | $953 | (21)% | $3,479 | $3,113 | 12% |
| Pre-tax adjusted margin | 7.9% | 10.4% | (250) bps | 12.1% | 11.4% | 70 bps |
| Medical care ratio | 82.6% | 80.5% | (210) bps | 77.2% | 80.3% | 310 bps |
| Expense ratio | 21.8% | 23.2% | 140 bps | 22.2% | 22.3% | 10 bps |
(In thousands)
| U.S. Medical Customers | As of September 30, 2020 | 2019 | % Change |
|---|---|---|---|
| U.S. Commercial | 2,120 | 2,078 | 2% |
| U.S. Government | 1,413 | 1,374 | 3% |
| Insured | 3,533 | 3,452 | 2% |
| Service | 11,781 | 12,043 | (2)% |
| Total | 15,314 | 15,495 | (1)% |
(In millions)
| As of September 30, 2020 | As of December 31, 2019 | % Change | |
|---|---|---|---|
| Unpaid claims and claim expenses – U.S. Medical | $3,200 | $2,892 | 11% |
Three and Nine Months Ended September 30, 2020 versus Three and Nine Months Ended September 30, 2019
Adjusted revenues. The increase for the three and nine months ended September 30, 2020 compared with the same periods in 2019 reflects customer growth in our U.S. Commercial insured and Medicare Advantage businesses, as well as higher premium rates due to anticipated underlying medical cost trend and the resumption of the health insurance industry tax. The increase for the nine months ended September 30, 2020 compared with the same period in 2019 includes the impact of premium relief programs for clients implemented in the second quarter of 2020 in response to significantly lower than historical utilization as individuals deferred care due to the COVID-19 pandemic.
Pre-tax adjusted income from operations. The decrease for the three months ended September 30, 2020 compared with the same period in 2019 reflects unfavorable prior period development primarily related to the second quarter of 2020, COVID-19 related impacts, and the return of the health insurance industry tax. COVID-19 related impacts include the net impact of the return of medical utilization to more typical levels, direct COVID-19 costs, as well as the costs of actions we have taken to support customers and providers, decreased specialty contributions, and lower net investment income. The increase for the nine months ended September 30, 2020 compared with the same period in 2019 reflects increased earnings from the U.S. Commercial and U.S. Government insured businesses due to deferral of care by our customers in response to the COVID-19 pandemic exceeding the cost of COVID-19 related care, partially offset by premium relief programs extended to employer clients and lower net investment income.
Medical care ratio. The medical care ratio increased for the three months ended September 30, 2020 compared with the same period in 2019 reflecting unfavorable prior period development primarily related to the second quarter of 2020 and COVID-19 related impacts, partially offset by the pricing effect of the health insurance industry tax. The decrease for the nine months ended September 30, 2020 compared with the same period in 2019 is due to the COVID-19 pandemic effects of significant deferred utilization experienced in April and May exceeding incremental costs of care, partially offset by premium relief programs extended to employer clients.
Expense ratio. The expense ratio decreased for the three months ended September 30, 2020 and was essentially flat for the nine months ended September 30, 2020 compared with the same periods in 2019 reflecting higher insured revenues and lower costs associated with operations-related litigation and compliance matters, partially offset by the resumption of the health insurance industry tax.
Other Items Affecting U.S. Medical Results
Unpaid Claims and Claim Expenses
Our unpaid claims and claim expenses liability was higher as of September 30, 2020 compared with December 31, 2019, primarily due to seasonality in our stop-loss products and membership growth in our Medicare Advantage business.
Medical Customers
Our medical customer base decreased at September 30, 2020 compared with the same period in 2019, reflecting a lower customer base in our National Accounts segment and increased disenrollment resulting from the economic impacts of the COVID-19 pandemic partially offset by growth in our Select segment and our Medicare Advantage business.
A medical customer is defined as a person meeting any one of the following criteria:
- is covered under a medical insurance policy, managed care arrangement or service agreement issued by us;
- has access to our provider network for covered services under their medical plan; or
- has medical claims that are administered by us.
International Markets Segment
As described in the introduction to Segment Reporting, performance of the International Markets segment is measured using pre-tax adjusted income from operations. Key factors affecting pre-tax adjusted income from operations for this segment are:
- premium growth, including new business and customer retention;
- benefit expenses as a percentage of premiums (loss ratio);
- selling, general and administrative expense and acquisition expense as a percentage of revenues (expense ratio and acquisition cost ratio); and
- the impact of foreign currency movements.
Results of Operations
(In millions)
| Financial Summary | Three Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) 2020 | Nine Months Ended September 30, 2019 | Change Favorable (Unfavorable) | |
|---|---|---|---|---|---|---|
| Adjusted revenues | $1,440 | $1,402 | 3% | $4,342 | $4,185 | 4% |
| Pre-tax adjusted income from operations | $208 | $194 | 7% | $809 | $607 | 33% |
| Pre-tax adjusted margin | 14.4% | 13.8% | 60 bps | 18.6% | 14.5% | 410 bps |
| Loss ratio | 57.4% | 57.6% | 20 bps | 55.1% | 56.8% | 170 bps |
| Acquisition cost ratio | 11.8% | 13.0% | 120 bps | 10.9% | 13.0% | 210 bps |
| Expense ratio (excluding acquisition costs) | 19.5% | 19.0% | (50) bps | 18.7% | 19.0% | 30 bps |
Three and Nine Months Ended September 30, 2020 versus Three and Nine Months Ended September 30, 2019
Adjusted revenues increased mainly due to business growth in Asia and Europe, partially offset by premium relief programs, primarily in Europe. The increase in adjusted revenues was also partially offset by unfavorable foreign currency movements for the nine months ended September 30, 2020.
Pre-tax adjusted income from operations increased for the three months ended September 30, 2020 due to lower acquisition and loss ratios, as well as business growth, partially offset by higher expense ratios. For the nine months ended September 30, 2020, the increase in pre-tax adjusted income from operations reflects lower acquisition, loss and expense ratios and business growth, primarily in Asia, partially offset by unfavorable foreign currency movements and lower net investment income. The ratios for both the three and nine months ended September 30, 2020 reflect the unfavorable impact of premium relief programs.
The segment’s loss ratio decreased reflecting lower medical utilization due to the COVID-19 pandemic, partially offset by premium relief programs. For the nine months ended September 30, 2020, the decrease in the loss ratio was also partially offset by the absence of 2019 reserve updates.
The acquisition cost ratio decreased reflecting an update to our commission deferral process and lower acquisition expenses in Asia, partially offset by premium relief programs.
The expense ratio (excluding acquisition costs) increased for the three months ended September 30, 2020 reflecting premium relief programs. For the nine months ended September 30, 2020, the decrease in the expense ratio was mainly driven by lower spend across markets.
Other Items Related to International Markets Results
South Korea is the single largest geographic market for our International Markets segment. For the nine months ended September 30, 2020, South Korea generated 37% of the segment’s adjusted revenues and 53% of the segment’s pre-tax adjusted income from operations.
Group Disability and Other
As described in the introduction of Segment Reporting, performance of Group Disability and Other is measured using pre-tax adjusted income from operations. Key factors affecting pre-tax adjusted income from operations are:
- premium growth, including new business and customer retention;
- net investment income;
- benefit expenses as a percentage of premiums (loss ratio); and
- selling, general and administrative expense as a percentage of revenues excluding net investment income (expense ratio).
Results of Operations
(In millions)
| Financial Summary | Three Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) 2020 | Nine Months Ended September 30, 2019 | Change Favorable (Unfavorable) | |
|---|---|---|---|---|---|---|
| Adjusted revenues | $1,314 | $1,284 | 2% | $3,981 | $3,889 | 2% |
| Pre-tax adjusted income from operations | $70 | $143 | (51)% | $279 | $376 | (26)% |
| Pre-tax adjusted margin | 5.3% | 11.1% | (580) bps | 7.0% | 9.7% | (270) bps |
Three and Nine Months Ended September 30, 2020 versus Three and Nine Months Ended September 30, 2019
Adjusted revenues increased primarily due to growth in disability, life and voluntary products, partially offset by lower investment income.
Pre-tax adjusted income from operations and margin decreased due to unfavorable life claims experience related to the COVID-19 pandemic, lower investment income and lower interest rates, partially offset by favorable results in our voluntary products.
Corporate
Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, severance, certain overhead and project costs and intersegment eliminations for products and services sold between segments.
(In millions)
| Financial Summary | Three Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) | Nine Months Ended September 30, 2020 | 2019 | Change Favorable (Unfavorable) |
|---|---|---|---|---|---|---|
| Pre-tax adjusted loss from operations | $(366) | $(442) | 17% | $(1,171) | $(1,385) | 15% |
77
Three and Nine Months Ended September 30, 2020 versus Three and Nine Months Ended September 30, 2019
Pre-tax adjusted loss from operations was lower, primarily reflecting lower interest expense.
INVESTMENT ASSETS
The following table presents our investment asset portfolio excluding separate account assets as of September 30, 2020 and December 31, 2019. Additional information regarding our investment assets is included in Notes 11, 12, 13 and 14 to the Consolidated Financial Statements.
(In millions)
| September 30, 2020 | December 31, 2019 | |
|---|---|---|
| Debt securities | $24,673 | $23,755 |
| Equity securities | 379 | 303 |
| Commercial mortgage loans | 1,979 | 1,947 |
| Policy loans | 1,347 | 1,357 |
| Other long-term investments | 2,698 | 2,403 |
| Short-term investments | 458 | 423 |
| Total | $31,534 | $30,188 |
| Investments classified as assets of business held for sale (1) | $(8,258) | $(7,709) |
| Investments per Consolidated Balance Sheets | $23,276 | $22,479 |
(1) The table above includes $8.3 billion as of September 30, 2020 and $7.7 billion as of December 31, 2019 of investments associated with the U.S. Group Disability and Life business that are held for sale to New York Life. Under the terms of the definitive agreement, some of the assets currently associated with the Group Disability and Life business can be substituted for other assets. The assets that will transfer to New York Life will be primarily debt securities and, to a lesser extent, commercial mortgage loans and short-term investments.
Debt Securities
Investments in debt securities include publicly-traded and privately-placed bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor. These investments are classified as available for sale and are carried at fair value on our balance sheet. Additional information regarding valuation methodologies, key inputs and controls is included in Note 12 to the Consolidated Financial Statements. More detailed information about debt securities by type of issuer and maturity dates is included in Note 11 to the Consolidated Financial Statements.
The following table reflects our portfolio of debt securities by type of issuer as of September 30, 2020 and December 31, 2019.
(In millions)
| September 30, 2020 | December 31, 2019 | |
|---|---|---|
| Federal government and agency | $634 | $733 |
| State and local government | 713 | 810 |
| Foreign government | 2,402 | 2,256 |
| Corporate | 20,409 | 19,420 |
| Mortgage and other asset-backed | 515 | 536 |
| Total | $24,673 | $23,755 |
78
Our debt securities portfolio increased during the first nine months of 2020 reflecting an increase in valuations due to decreasing yields and net purchase activity. As of September 30, 2020, $22.1 billion, or 90% of the debt securities in our investment portfolio were investment grade (Baa and above, or equivalent) and the remaining $2.6 billion were below investment grade. The majority of the bonds that are below investment grade are rated at the higher end of the non-investment grade spectrum. These quality characteristics have not materially changed from the prior year and are consistent with our investment strategy. Investments in debt securities are diversified by issuer, geography and industry as appropriate. On an aggregate basis, the debt securities portfolio continues to perform according to original investment expectations. However, due to the economic impacts of the COVID-19 pandemic, there are certain issuers, particularly within the aviation, energy and hospitality sectors that are showing signs of distress, primarily in the form of requests for temporary covenant relief. There were no material unrealized losses in any of these sectors as of the reporting date. We continue to monitor the economic environment and its effect on our portfolio, and consider the impact of various factors in determining the allowance for credit losses on debt securities, which is discussed in Note 11 to the Consolidated Financial Statements.
Foreign government obligations are concentrated in Asia, primarily South Korea, consistent with our risk management practice and local regulatory requirements of our international business operations. Corporate debt securities include private placement assets of $7.9 billion. These investments are generally less marketable than publicly-traded bonds; however yields on these investments tend to be higher than yields on publicly-traded bonds with comparable credit risk. We perform a credit analysis of each issuer and require financial and other covenants that allow us to monitor issuers for deteriorating financial strength and pursue remedial actions, if warranted.
In addition to amounts classified as debt securities in our Consolidated Balance Sheets, we participate in an insurance joint venture in China with a 50% ownership interest. This entity had an investment portfolio of approximately $10.3 billion supporting its business that is primarily invested in Chinese corporate and government debt securities. We account for this joint venture on the equity method of accounting and report it in Other assets. There were no investments with a material unrealized loss as of September 30, 2020.
Commercial Mortgage Loans
Our commercial mortgage loans are fixed rate loans, diversified by property type, location and borrower. Loans are secured by high quality commercial properties, located in strong institutional markets, and are generally made at less than 65% of the property’s value at origination of the loan. Property value, debt service coverage, quality, building tenancy and stability of cash flows are all important financial underwriting considerations. We hold no direct residential mortgage loans and do not originate or service securitized mortgage loans.
Overall, commercial real estate capital market activity has been negatively impacted by COVID-19 with concentrated weakness in hotels and regional malls. Our mortgage loan portfolio is well diversified by property type and geography with no material exposure to hotels and no exposure to regional shopping malls.
As of September 30, 2020, the $2.0 billion commercial mortgage loan portfolio consisted of approximately 65 loans that are in good standing. Given the quality and diversity of the underlying real estate, positive debt service coverage and significant borrower cash invested generally ranging between 30 and 40%, we remain confident that the vast majority of borrowers will continue to perform as expected under their contract terms. For further discussion of the results and changes in key loan metrics, see Note 11 to the Consolidated Financial Statements.
Other Long-term Investments
Other long-term investments of $2.7 billion as of September 30, 2020 included investments in securities limited partnerships and real estate limited partnerships, direct investments in real estate joint ventures, and other deposit activity that is required to support various insurance and health services businesses. The increase in other long-term investments is driven by net new funding activity. Our approximately $2 billion of limited partnership entities typically invest in mezzanine debt or equity of privately-held companies (securities partnerships) and equity real estate. Given our subordinate position in the capital structure of these underlying entities, we assume a higher level of risk for higher expected returns. To mitigate risk, these investments are diversified across approximately 175 separate partnerships and approximately 90 general partners who manage one or more of these partnerships. Also, the underlying investments are diversified by industry sector or property type and geographic region. No single partnership investment exceeded 4% of our securities and real estate partnership portfolio.
Income from our limited partnership investments is generally reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Accordingly, our net investment income in the third quarter largely reflects the underlying financial information from the second quarter of 2020. We could experience losses during the remainder of 2020 and into future periods, but the magnitude of these losses will depend in part on the length and extent of the economic disruption, the speed of the recovery, and the overall economic impacts.
Investment Outlook
The impact of COVID-19 on the economy, despite unprecedented monetary and fiscal support, and the uncertainty as to the strength and sustainability of the recovery prior to a widely available vaccine continue to dominate financial markets. Net investment income was positively impacted by third quarter valuations of mezzanine, private equity, and real estate fund asset holdings based on improving economic prospects, as also reflected in public equity valuations. However, the low interest rate environment continues to pressure income from both short-term and longer-term investments. U.S. treasury rates remain near all-time lows and the wider market credit spreads experienced during the beginning of the second quarter have meaningfully narrowed, resulting in historically low yields for investment grade assets. We continue to actively monitor the economic impact of the pandemic, as well as fiscal and monetary responses, and their potential impact on the portfolio. Our full year net investment income projections reflect continued market volatility and portfolio impacts, particularly in certain sectors such as retail, hospitality, aviation and energy, as well as other areas most severely impacted by COVID-19. Future realized and unrealized investment results will be driven largely by market conditions that exist when a transaction occurs or at the reporting date. These future conditions are not reasonably predictable; however, we believe that the vast majority of our investments will continue to perform under their contractual terms. Based on our strategy to match the duration of invested assets to the duration of insurance and contractholder liabilities, we expect to hold a significant portion of these assets for the long term. Although future impairment losses resulting from interest rate movements and credit deterioration due to both investment-specific and the global economic uncertainties discussed above remain possible, we do not expect these losses to have a material adverse effect on our financial condition or liquidity.
MARKET RISK
Financial Instruments
Our assets and liabilities include certain financial instruments subject to the risk of potential losses from adverse changes in market rates and prices. Our primary market risk exposures are interest rate risk and foreign currency exchange rate risk. We encourage you to read this in conjunction with “Market Risk – Financial Instruments” included in the MD&A section of our 2019 Form 10-K. Given the transactions in our long-term debt further described in Note 8 to the Consolidated Financial Statements, in the event of a 100 basis point increase in interest rates, the fair value of the Company's long-term debt would decrease approximately $2.9 billion at September 30, 2020, compared to approximately $2.5 billion at December 31, 2019. Other than this, there were no material changes in our risk exposures from those reported in our 2019 Form 10-K.
Market risk
As filed, 225 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Information responsive to this item is contained under the caption “Market Risk” in Item 2 above, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and is incorporated herein by reference.
Controls and procedures
As filed, 1,149 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Based on an evaluation of the effectiveness of Cigna’s disclosure controls and procedures conducted under the supervision and with the participation of Cigna’s management (including Cigna’s Chief Executive Officer and Chief Financial Officer), Cigna's Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, Cigna’s disclosure controls and procedures are effective to ensure that information required to be disclosed by Cigna in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to Cigna’s management, including Cigna’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
During the period covered by this report, there have been no changes in Cigna’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, Cigna’s internal control over financial reporting.
Risk factors
As filed, 479 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 as such Risk Factors are supplemented by the information contained in Part II, Item 1A of our Form 10-Q for the quarter ended March 31, 2020. There have been no material changes to our previously reported Risk Factors.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $40.95bn | us-gaap:Revenues |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $118.69bn | us-gaap:Revenues |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $26.62bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $76.42bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2020-07-01 to 2020-09-30 | $3.30bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2020-01-01 to 2020-09-30 | $10.11bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $2.11bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | $6.81bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $406.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $1.14bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $1.40bn | us-gaap:ProfitLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $4.35bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $3.78 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $11.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $3.81 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $11.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 367,190,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 370,831,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $6.06bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 9 months2020-01-01 to 2020-09-30 | $2.35bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-09-30 | $5.34bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $34.56bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $160.04bn | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $43.89bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $111.95bn | us-gaap:Liabilities |
| Current portion of debt | At period end2020-09-30 | $6.45bn | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2020-09-30 | $1.55bn | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2020-09-30 | $48.03bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739940-20-000021. Last ingested by Listed: Nov 5, 2026, 13:13 ET. Listed shows no prices and gives no investment advice.